<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003658</url>
  </required_header>
  <id_info>
    <org_study_id>98-083</org_study_id>
    <secondary_id>CDR0000066751</secondary_id>
    <secondary_id>NCI-G98-1482</secondary_id>
    <nct_id>NCT00003658</nct_id>
  </id_info>
  <brief_title>Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers</brief_title>
  <official_title>A Phase I-II Study of Pentostatin With Cyclophosphamide for Previously Treated Patients With Intermediate and High-Risk Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate tumor cells&#xD;
      and either kill them or deliver tumor-killing substances to them without harming normal&#xD;
      cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining pentostatin,&#xD;
      cyclophosphamide, and rituximab in treating patients who have chronic lymphocytic leukemia or&#xD;
      other B-cell cancers that have been treated previously.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the dose of cyclophosphamide, with filgrastim (G-CSF) support, that can be&#xD;
           safely administered with pentostatin and rituximab in patients with previously treated&#xD;
           intermediate- or high-risk chronic lymphocytic leukemia or other low-grade B-cell&#xD;
           malignancies. (Phase I closed to accrual effective 11/27/2001.)&#xD;
&#xD;
        -  Characterize the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the incidence of response in these patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of cyclophosphamide (CTX).&#xD;
&#xD;
        -  Phase I: Patients receive CTX IV followed by pentostatin IV on day 1 of course 1.&#xD;
           Patients also receive filgrastim (G-CSF) subcutaneously once daily beginning on day 3&#xD;
           and continuing until blood counts recover. During the second and subsequent courses,&#xD;
           patients receive CTX IV, pentostatin IV, and rituximab IV on day 1. Patients also&#xD;
           receive G-CSF as in course 1. Treatment repeats every 3 weeks for 3 courses in the&#xD;
           absence of disease progression or unacceptable toxicity. Patients with at least a&#xD;
           partial response after the third course receive an additional 3 courses.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of CTX until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      (Phase I closed to accrual effective 11/27/2001.)&#xD;
&#xD;
        -  Phase II: Patients receive CTX at the recommended phase II dose and treatment as above.&#xD;
&#xD;
      Patients are followed at least every 3 months for 1 year and then periodically thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for the phase I portion of this&#xD;
      study. (Phase I closed to accrual effective 11/27/2001.) A total of 14-30 patients will be&#xD;
      accrued for the phase II portion of this study within 2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentostatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Intermediate- or high-risk chronic lymphocytic leukemia (CLL) as defined by the&#xD;
             three-stage Rai system&#xD;
&#xD;
               -  Rai intermediate disease must be active disease (including weight loss, fatigue,&#xD;
                  fevers, evidence of progressive marrow failure, splenomegaly, progressive&#xD;
                  lymphadenopathy, and progressive lymphocytosis with a rapid doubling time)&#xD;
&#xD;
          -  Other low-grade B-cell neoplasms, including small lymphocytic lymphoma (and its&#xD;
             variants), Waldenstrom's macroglobulinemia, and follicular lymphoma allowed&#xD;
&#xD;
          -  Autoimmune hemolytic anemia or autoimmune thrombocytopenia allowed regardless of&#xD;
             disease stage&#xD;
&#xD;
          -  B-cells demonstrated by immunophenotypic (or immunohistochemical) analysis of the&#xD;
             malignant lymphocytes&#xD;
&#xD;
          -  Must be previously treated&#xD;
&#xD;
          -  For CLL, absolute lymphocytosis in the blood at least 5,000 lymphocytes/mm^3 OR&#xD;
&#xD;
          -  Bone marrow lymphocytosis at least 30% of all nucleated cells&#xD;
&#xD;
          -  No Rai intermediate-risk disease that meets the criteria of Montserrat &quot;smoldering&#xD;
             leukemia&quot; NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been&#xD;
             adopted by PDQ. The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace&#xD;
             the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However,&#xD;
             this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 4 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infections requiring systemic antibiotics&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  Concurrent intravenous immunoglobulin allowed&#xD;
&#xD;
          -  Concurrent epoetin alfa allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent prednisone therapy allowed as long as dose is stable or decreasing over the&#xD;
             past 4 weeks&#xD;
&#xD;
          -  No increase in prednisone therapy while on study&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Adam Weiss, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006 Apr 1;24(10):1575-81. doi: 10.1200/JCO.2005.04.3836. Epub 2006 Mar 6.</citation>
    <PMID>16520464</PMID>
  </results_reference>
  <results_reference>
    <citation>Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, Frankel SR, Kossman SE, Horgan D. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003 Apr 1;21(7):1278-84. doi: 10.1200/JCO.2003.08.100.</citation>
    <PMID>12663715</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

